Patents Assigned to U.S. Dept. of Health and Human Services (DHHS)
-
Patent number: 11872394Abstract: Described herein are systems and methods for the treatment of pain using electrical nerve conduction block (ENCB). Contrary to other methods of pain treatment, the ENCB can establish a direct block of neural activity, thereby eliminating the pain. Additionally, the ENCB can be administered without causing electrochemical damage. An example method can include: placing at least one electrode contact in electrical communication with a region of a subject's spinal cord; applying an electrical nerve conduction block (ENCB) to a nerve in the region through the at least one electrode contact; and blocking neural activity with the ENCB to reduce the pain or other unwanted sensation in the subject.Type: GrantFiled: May 13, 2021Date of Patent: January 16, 2024Assignees: CASE WESTERN RESERVE UNIVERAITY, NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENTInventors: Niloy Bhadra, Narendra Bhadra, Kevin L Kilgore, Scott Lempka, Jesse Wainright, Tina Vrabec, Manfred Franke
-
Patent number: 11845955Abstract: The present disclosure relates to a simple, fast, and low cost method for 3D microvascular imaging, termed “scatter labeled imaging of microvasculature in excised tissue” (SLIME). The method can include perfusing a contrast agent through vasculature of a tissue sample. The contrast agent can include colloids and a dispersant. After the contrast agent is perfused through the vasculature, the vasculature of the tissue sample can be treated with a molecule that cross links with at least a portion of the dispersant to form a sticky, non-Newtonian polymer that prevents leakage of the contrast agent out of the vasculature of the tissue sample. The tissue sample can then be immersed in a solution comprising a clearing agent and subsequently imaged.Type: GrantFiled: August 1, 2022Date of Patent: December 19, 2023Assignees: CASE WESTERN RESERVE UNIVERSITY, NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT NIH DIVISION OF EXTRAMURAL INVENTIONS AND TECHNOLOGY RESOURCES (DEITR)Inventors: Michael W. Jenkins, Yehe Liu
-
Patent number: 11708612Abstract: Provided herein, inter alia, are improved methods and systems of determining immunotherapy response in subjects prior and during treatment. Provided herein are methods of detecting gene expression in T cells and in monocytes as well as measuring relative abundance of particular immune cell populations and determining responsiveness to anticancer immunotherapy.Type: GrantFiled: December 2, 2020Date of Patent: July 25, 2023Assignee: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENTInventors: Andrea Bild, Jason I. Griffiths
-
Patent number: 11701361Abstract: Methods of using a phosphoinositide 3-kinase p110-delta inhibitor to treat, delay the onset, or slow the progression of an autoimmune disease or disorder in a subject, without suppressing the subject's B cell responses to exogenous antigens or rendering the subject immunocompromised, as well as pharmaceutical compositions containing phosphoinositide 3-kinase p110-delta inhibitors in amounts suitable for convenient and accurate administration within these therapeutic methods.Type: GrantFiled: January 7, 2019Date of Patent: July 18, 2023Assignees: NATIONAL INSTITUTES OF HEALTH (NCH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT NIH DIVISION OF EXTRAMURAL INVENTIONS AND TECHNOLOGY RESOURCES (DEITR), THE REGENTS OF THE UNIVERSITY OF COLORADOInventors: John Cambier, Elizabeth Franks
-
Patent number: 11666569Abstract: An HDAC6-specific inhibitor (i.e., a compound of Formula I or II) is shown to reduce the pathogenesis associated with polycystic disease. Administration of an HDAC6-specific inhibitor attenuated many of the symptoms characteristic of polycystic liver disease including cyst formation, cyst growth and cholangiocyte proliferation. Treatment with a HDAC6-specific inhibitor also increased the amount of bile duct acetylated tubulin and ?-catenin phosphorylation and/or acetylation while reducing bile duct ?-catenin synthesis. These results demonstrate that HDAC6 is overexpressed in cystic cholangiocytes and that its pharmacological inhibition reduces cholangiocyte proliferation and cyst growth.Type: GrantFiled: May 14, 2020Date of Patent: June 6, 2023Assignee: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS) U.S. GOVERNMENTInventors: Sergio A. Gradilone, Nicholas F. LaRusso
-
Patent number: 11612619Abstract: Compositions, methods, and systems for modifying sterol metabolism in a subject is disclosed. In some embodiments, the subjects may be administered one or more mammalian cells modified to express at least one sterol degrading enzyme derived from a bacterium. In many embodiments, the cell is a macrophage or monocyte stably expressing three or more enzymes that aid in opening the ? ring of cholesterol. The disclosed compositions and methods may be useful in lowering cholesterol levels in a subject in need thereof. In some embodiments, the subject may have a genetic predisposition to atherosclerosis.Type: GrantFiled: November 1, 2019Date of Patent: March 28, 2023Assignee: National Institute of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), U.S. GovernmentInventors: Richard Eric Honkanen, Brandon Marshall D'Arcy, Mark Raymond Swingle
-
Patent number: 11230722Abstract: Novel compounds and compositions containing (R)-3-hydroxybutyrate derivatives are disclosed. The compounds and compositions can be used as nutritional supplements to increase physical performance and as therapeutics to ameliorate symptoms of medical conditions, particularly neurological conditions, such as Alzheimer's and similar conditions. Novel methods for making R-3-hydroxybutyrate derivatives also are disclosed. Exemplary methods employ a supercritical solvent, such as supercritical carbon dioxide, and employ a lipase catalyzed esterification or transesterification reaction to produce the (R)-3-hydroxybutyrate derivatives.Type: GrantFiled: March 7, 2018Date of Patent: January 25, 2022Assignees: Oxford University Innovation Limited, U.S. Dept. Of Health and Human Services, (DHHS), U.S. GovernmentInventors: Richard Lewis Veech, Michael Todd King, Kieran Clarke
-
Patent number: 11135187Abstract: Compositions and methods for treating diabetic retinopathy or symptoms thereof are provided. The disclosed compositions and methods for treating diabetic retinopathy contravene the existing paradigm that Renin-Angiotensin System (RAS) blockade alone can treat, prevent, or reduce diabetic retinopathy. The disclosed compositions and methods include a combination or alternation of EET antagonists and ATI antagonists.Type: GrantFiled: August 21, 2018Date of Patent: October 5, 2021Assignees: National Institutes of Health (NIH), U.S. Dept. of Health Human Services, (DHHS), U.S. Government NIH Division of Extramural Inventions and Technology Resources (DEITR)Inventors: Mong Heng Wang, Mohamed Al-Shabrawey
-
Patent number: 11090660Abstract: The present technology relates to improved device and methods of use of insulator-based dielectrophoresis. This device provides a multi-length scale element that provides enhanced resolution and separation. The device provides improved particle streamlines, trapping efficiency, and induces laterally similar environments. Also provided are methods of using the device.Type: GrantFiled: August 10, 2017Date of Patent: August 17, 2021Assignees: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY, NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENTInventors: Mark Hayes, Claire Crowther, Paul Jones
-
Patent number: 11040215Abstract: The present invention relates to compositions and methods configured to deliver a stimulus (e.g., a therapeutic agent or a therapeutically beneficial signal) to a cell, tissue, organ, or organism. The stimulus is applied at least twice, and the first and second applications are separated by a rest period in which no further stimulus is actively applied. The rest period is of a duration (e.g., about 1-6 hours) sufficient to provoke an enhanced response to the second stimulus.Type: GrantFiled: July 20, 2018Date of Patent: June 22, 2021Assignee: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS). U.S. GOVERNMENT NIH DIVISION OF EXTRAMURAL INVENTIONS AND TECHNOLOGY RESOURCES (DEITR)Inventors: Clinton Rubin, Janet Rubin
-
Patent number: 11041011Abstract: T cell receptors that specifically recognize hAFP158 and methods of their use are provided.Type: GrantFiled: May 2, 2018Date of Patent: June 22, 2021Assignees: Augusta University Research Institute, Inc., National Institutes of Health (NIH), U.S. Dept. of Health And Human Services (DHHS), U.S. Government NIH Division of Extramural Inventionsl and Technology Resources (DEITR)Inventors: Yukai He, Wei Zhu, Esteban Celis, Yibing Peng, Lan Wang
-
Patent number: 10954489Abstract: A liver-mimetic device and method include a 3D polymer scaffold having a matrix of liver-like lobules with hepatic-functioning particles encapsulated within the lobules. In some embodiments, each liver-like lobule is hexagonal in structure and the matrix is in a honeycomb arrangement. In some embodiments, the hepatic-functioning particles are hepatic progenitor cells. In other embodiments, the hepatic-functioning particles are polymer nanoparticles adapted to capture pore-forming toxins.Type: GrantFiled: June 4, 2014Date of Patent: March 23, 2021Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS)Inventors: Xin Qu, Maling Gou, Wei Zhu, Shaochen Chen
-
Patent number: 10660890Abstract: An HDAC6-specific inhibitor (i.e., a compound of Formula I or II) is shown to reduce the pathogenesis associated with polycystic disease. Administration of an HDAC6-specific inhibitor attenuated many of the symptoms characteristic of polycystic liver disease including cyst formation, cyst growth and cholangiocyte proliferation. Treatment with a HDAC6-specific inhibitor also increased the amount of bile duct acetylated tubulin and ?-catenin phosphorylation and/or acetylation while reducing bile duct ?-catenin synthesis. These results demonstrate that HDAC6 is overexpressed in cystic cholangiocytes and that its pharmacological inhibition reduces cholangiocyte proliferation and cyst growth.Type: GrantFiled: October 24, 2014Date of Patent: May 26, 2020Assignee: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT NIH DIVISION OF EXTRAMURAL INVENTIONS AND TECHNOLOGY RESOURCES (DEITR)Inventors: Sergio A. Gradilone, Nicholas F. LaRusso
-
Patent number: 10626138Abstract: Provided herein are analogs of unnatural nucleotides bearing predominantly hydrophobic nucleobase analogs that form unnatural base pairs during DNA polymerase-mediated replication of DNA or RNA polymerase-mediated transcription of RNA. In this manner, the unnatural nucleobases can be introduced in a site-specific way into oligonucleotides (single or double stranded DNA or RNA), where they can provide for site-specific cleavage, or can provide a reactive linker than can undergo functionalization with a cargo-bearing reagent by means of reaction with a primary amino group or by means of click chemistry with an alkyne group of the unnatural nucleobase linker.Type: GrantFiled: August 8, 2014Date of Patent: April 21, 2020Assignees: THE SCRIPPS RESEARCH INSTITUTE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT NIH DIVISION OF EXTRAMURAL INVENTIONS AND TECHNOLOGY RESOURCES (DEITR)Inventors: Floyd E. Romesberg, Denis A. Malyshev, Lingjun Li, Thomas Lavergne, Zhengtao Li
-
Patent number: 10196596Abstract: Disclosed herein are capillary fabrication devices comprising living cells within a support medium. Culture of the cells produces viable lumenized capillary networks with natural or pre-determined geometries and ECM and basement membrane associated with the capillary networks. The capillary networks and the ECM and basement membrane detachable from the capillary networks are useful for tissue engineering applications.Type: GrantFiled: February 22, 2016Date of Patent: February 5, 2019Assignee: National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), The United States of America NIH Division of Extramural Inventions and Technology Resources (DEITR)Inventors: James A. Glazier, Abdelkrim Alileche, Abbas Shirinifard, Dragos Amarie
-
Patent number: 10046024Abstract: A composition which is reversible inhibitor of at least one neuron-specific PDZ domain comprising wherein R is a molecular transporter with or without a linker amino acid; R1 is at least about one amino acid covalently bound; and, R2 is isoleucine, leucine, alanine, phenylalanine, or valine, and methods of use.Type: GrantFiled: June 28, 2016Date of Patent: August 14, 2018Assignee: The United States of America, as represented by National Institutes of Health (NIH), U.S. Dept of Health and Human Services (DHHS), NIH Division of Extramural Inventions and Technology Resource (DEITR)Inventors: Mark Spaller, John Marshall, Dennis J. Goebel
-
Patent number: 9809797Abstract: A method of carrying out adoptive immunotherapy by administering a subject an antigen-specific cytotoxic T lymphocytes (CTL) preparation in a treatment-effective amount is described. In the method, the CTL preparation is preferably administered as a preparation of an in vitro antigen-stimulated and expanded primate CTL population, the CTL population: (i) depleted of FoxP3+ T lymphocytes prior to antigen stimulation; (ii) antigen-stimulated in vitro in the presence of interleukin-21; or (iii) both depleted of FoxP3+ T lymphocytes prior to antigen stimulation and then antigen-stimulated in vitro in the presence of interleukin-21. Methods of preparing such compositions, and compositions useful for carrying out the adoptive immunotherapy, are also described.Type: GrantFiled: September 25, 2008Date of Patent: November 7, 2017Assignee: NATIONAL INSTITUTES OF HEALTH (NIH) U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS) DIVISION OF EXTRAMURAL INVENTIONS AND TECHNOLOGYInventors: Cassian Yee, Yongqing Li
-
Patent number: 9770186Abstract: Methods and apparatus for operating an MRI system is provided. The disclosure provides a diffusion-prepared driven-equilibrium preparation for an imaging volume and acquiring 3-dimensional k-space data from said prepared volume by a plurality of echoplanar readouts of stimulated echoes. An excitation radio-frequency signal and first and second inversion RF signals are provided to define a field-of-view (FOV).Type: GrantFiled: February 19, 2013Date of Patent: September 26, 2017Assignee: National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), The United States of America NIH Division of Extramural Inventions and Technology Resources (DEITR)Inventors: Eun-Kee Jeong, Dennis L Parker, Kim Seong-Eun Choi, Evgueni G Kholmovski
-
Patent number: 9737478Abstract: The invention contemplates compositions for the treatment of malaria comprising an anti-malaria drug and an adjuvant which promotes vasodilation and methods of using same.Type: GrantFiled: September 13, 2010Date of Patent: August 22, 2017Assignee: National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), The United States of America NIH Division of Extramural Inventions and Technology Resources (DEITR)Inventors: Leonardo Jose de Moura Carvalho, Pedro Cabrales
-
Patent number: 9687172Abstract: A system determines motion correction data for use in diffusion MR imaging using an RF signal generator and magnetic field gradient generator which sequentially acquire in a single first direction through a volume, first and second slice sets individually comprising multiple individual diffusion image slices. The first set of slices and the second set of slices are spatially interleaved within the volume, by providing in acquiring the second slice set, a low flip angle RF pulse successively followed by a non-diffusion image data readout magnetic field gradient for acquisition of data representing a two dimensional (2D) non-diffusion image used for motion detection of the first slice set successively followed by, a first diffusion imaging RF pulse followed by a first diffusion imaging phase encoding magnetic field gradient for preparation for acquiring data representing a diffusion image slice of the second slice set.Type: GrantFiled: June 20, 2012Date of Patent: June 27, 2017Assignees: National Institute of Health (NIH), The United States of America, U.S. Dept. of Health and Human Services (DHHS), Siemens Healthcare GmbHInventors: Himanshu Bhat, Andre Jan Willem Van Der Kouwe, Matthew Dylan Tisdall, Keith Aaron Heberlein